# Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC

> **NCT03099486** · PHASE2 · TERMINATED · sponsor: **Fox Chase Cancer Center** · enrollment: 2 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** 5-FU
- **DRUG:** Leucovorin

## Key facts

- **NCT ID:** NCT03099486
- **Lead sponsor:** Fox Chase Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-06
- **Primary completion:** 2020-06-02
- **Final completion:** 2020-06-02
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Administrative change
- **Last updated:** 2022-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03099486

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03099486, "Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03099486. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*